Pioglitazone/glimepiride

Pioglitazone/glimepiride, sold under the brand name Duetact among others, is a fixed-dose combination anti-diabetic medication for the treatment of type 2 diabetes.[2][1] It contains the thiazolidinedione pioglitazone and the sulfonylurea glimepiride.[2][1] It is taken by mouth.[2][1]

Pioglitazone/glimepiride
Combination of
PioglitazoneThiazolidinedione
GlimepirideSulfonylurea
Clinical data
Trade namesDuetact, Tandemact
AHFS/Drugs.comUK Drug Information
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

The most common side effects include upper respiratory tract infections (such as colds), hypoesthesia (reduced sense of touch), bone fractures, weight gain, dizziness, flatulence (gas) and edema (swelling).[1]

Pioglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.[1] Glimepiride is a sulphonylurea: it stimulates the pancreas to produce more insulin.[1] Pioglitazone/glimepiride was approved for medical use in the United States in July 2006, and in the European Union in January 2007.[1][3][4]

Medical uses

In the United States pioglitazone/glimepiride is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone.[2][3][5]

In the European Union pioglitazone/glimepiride is indicated for the treatment of people with type 2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.[1]

References
  1. "Tandemact EPAR". European Medicines Agency (EMA). Retrieved 27 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. "Duetact- pioglitazone and glimepiride tablet". DailyMed. 5 February 2019. Retrieved 27 July 2020.
  3. "Duetact approval letter" (PDF). U.S. Food and Drug Administration (FDA). 27 July 2006. This article incorporates text from this source, which is in the public domain.
  4. "Drug Approval Package: Duetact (pioglitazone HCl + glimepiride) NDA #021925". U.S. Food and Drug Administration (FDA). 4 September 2008.
  5. "Pioglitazone (marketed as Actos, Actoplus Met, Duetact, and Oseni) Inf". U.S. Food and Drug Administration (FDA). 8 September 2016. Retrieved 27 July 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.